Complete inactivation of blood borne pathogen trypanosoma cruzi in stored human platelet concentrates and plasma treated with 405nm violet-blue light

Katarzyna I. Jankowska, Rana Nagarkatti, Nirmallya Acharyya, Neetu Dahiya, Caitlin Stewart, Ruairidh Macpherson, Mark Wilson, John Anderson, Scott MacGregor, Michelle Maclean, Neil Dey, Alain Debranant, Chintamani D Atreya

Research output: Contribution to journalArticle

Abstract

The introduction of pathogen reduction technologies (PRTs) to inactivate bacteria, viruses and parasites in donated blood components stored for transfusion adds to the existing arsenal towards reducing the risk of transfusion-transmitted infectious diseases (TTIDs). We have previously demonstrated that 405nm violet-blue light effectively reduces blood-borne bacteria in stored human plasma and platelet concentrates. In this report, we investigated the microbicidal effect of 405nm light on one important bloodborne parasite Trypanosoma cruzi that causes Chagas disease in humans. Our results demonstrated that a light irradiance at 15 mWcm−2 for 5h, equivalent to 270 Jcm−2, effectively inactivated T. cruzi by over 9.0 Log10, in plasma and platelets that were evaluated by a MK2 cell infectivity assay. Giemsa stained T. cruzi infected MK2 cells showed that the light-treated parasites in plasma and platelets were deficient in infecting MK2 cells and did not differentiate further into intracellular amastigotes unlike the untreated parasites. The light-treated and untreated parasite samples were then evaluated for any residual infectivity by injecting the treated parasites into Swiss Webster mice, which did not develop infection even after the animals were immunosuppressed, further demonstrating that the light treatment was completely effective for inactivation of the parasite; the light-treated platelets had similar in vitro metabolic and biochemical indices to that of untreated platelets. Overall, these results provide a proof of concept towards developing 405nm light treatment as a pathogen reduction technology (PRT) to enhance the safety of stored human plasma and platelet concentrates from bloodborne T. cruzi, which causes Chagas disease.
Original languageEnglish
Article number617373
Number of pages11
JournalFrontiers in Medicine
DOIs
Publication statusPublished - 24 Nov 2020

Keywords

  • trypanosoma cruzi
  • parasite
  • platelets
  • plasma
  • pathogen-reduction technologies
  • 405nm light

Fingerprint Dive into the research topics of 'Complete inactivation of blood borne pathogen trypanosoma cruzi in stored human platelet concentrates and plasma treated with 405nm violet-blue light'. Together they form a unique fingerprint.

Cite this